Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV-C for Occult CNV in AMD
NCT00220805Phase 2Completed
- Sponsor
- Grifols
- Start
- Jan 2004
- Primary completion
- May 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous human immunoglobulin in age-related macular degeneration (AMD), sponsored by Grifols. Started Jan 2004; status: completed.
02
Drugs
intravenous human immunoglobulin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00220805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220805.